Abologix is a startup based in Switzerland.
Abologix is a biopharmaceutical company developing monoclonal antibodies targeting Junction Adhesion Molecule C (JAM-C) and Olfactomedin-like protein 3 (Olfml3) for cancer therapies, particularly focusing on oncological indications.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.